88% Profit Surge Expected on Oct. 28: Why Peter Thiel-Backed Vista Energy is Wall Street’s Favorite Shale Play
Quick Read
-
VIST surged 88% over the past year to $74.84, with 14 analysts rating it a Buy and an average target of $99.60.
-
Wall Street expects Q3 revenue of $1.17 billion, up 66% from Q3 2025, as the first full quarter of Equinor assets hits the books.
Sensex Today | Stock Market LIVE Updates: GIFT Nifty signals weak start; US, Asian markets decline
Market on Friday | Markets recover from day’s lows, but sell-off extends to 4th day; Nifty at 22,600
Indian equity markets extended their losing streak for the fourth consecutive session on Friday, October 23, with the Nifty recovering to around 22,600 after slipping below 22,400 amid broad-based selling across sectors.
Extreme Polarization in the Stock Market and the 'FUDD' Trap: The Structure Where Stock Prices Don't Rise Even on Earnings Beats, the Return to Quality Stocks, and Strategic …
Hello, this is Kimama na Yaasu.
An unprecedented, harsh, and irrational ‘extreme bifurcation’ is underway in the stock market.
Observing the current earnings season, a terrifying phenomenon has become routine. Even when companies announce strong earnings (beats) that exceed prior market expectations (consensus), stock prices either do not react at all or show only a slight increase.
Read MoreBloom Energy Is 44% Below Its June Record. Here’s the Number That Sank It After Earnings
Key Takeaways
-
Bloom Energy fell 11% on Oct. 23 to close about 44% below its June 22 record,
Netflix Price Prediction: Where the Stock Goes After a Year of Doubts
Netflix just beat earnings and still got punished, losing nearly half its value over the past year while its margins quietly widened. Something in that math does not add up, and the answer shapes where the stock goes from here.
Our 24/7 Wall St. price target for Netflix (NASDAQ:NFLX | NFLX Price Prediction) is $78.99 over the next 12 months.
» Read more about: Netflix Price Prediction: Where the Stock Goes After a Year of Doubts »
Read MoreThe Burst
How a $300 Mistake Opened a $1 Billion Market
Novo Nordisk, the pharmaceutical giant behind weight-loss blockbusters Ozempic and Wegovy, just let a key patent on semaglutide lapse in Canada because it forgot to pay a routine maintenance fee, the pharmaceutical equivalent of forgetting to renew your car registration.
As a result, generic versions of semaglutide, the active ingredient in both drugs,
» Read more about: How a $300 Mistake Opened a $1 Billion Market »
Read MoreThe Ivy
Is This The #1 Semi Stock To Buy Now?
AI stocks have been on fire in 2025. After Oracle and other hyperscalers revealed record-breaking capital expenditures, most semiconductor names raced back toward all-time highs. Yet one company that sits at the very heart of chip production has been noticeably absent from the party, ASML.
Despite that enviable position, the stock hasn’t kept pace with the AI rally.
» Read more about: Is This The #1 Semi Stock To Buy Now? »
Read MoreThe Spotlight
Trade Like a Billionaire
Few traders in history have the capacity to seamlessly transition across asset classes, zooming out to see the big macro picture and in to see the minutia of a company’s 10Q but Stan Druckenmiller ranks as one of the few who have succeeded in so doing.
Stan’s thesis has been that the Fed is really in a bind,